BPC-157 + TB-500 (10 mg + 10 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. For 10 unit (0.10 mL) or smaller administrations during Weeks 1 to

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
3. Gently swirl or roll until fully dissolved (do not shake).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light. At 6.67 mg/mL total, 1 unit = 0.01 mL » 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; use within 14 days; avoid freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on a 4 to 8 week daily protocol (standard approach at ~1 mg/day maintenance).

Peptide Vials (BPC+TB 20 mg Blend):

• 4 weeks (28 doses at ~0.67 to 1.0 mg/day): 2 vials.
• 6 weeks (42 doses): 3 vials.
• 8 weeks (56 doses): 3 to 4 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 4 weeks: 28. 6 weeks: 42. 8 weeks: 56.

Bacteriostatic Water (10 mL bottles):

• 4 weeks (2 vials): 1 bottle. 6 weeks (3 vials): 1 bottle. 8 weeks (4 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 swabs (2 x 100-count box).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose properly in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and maintain absorption.
• Inject near the site of injury when targeting localized tissue repair (within anatomical reason).
• Document daily dose and site rotation to maintain consistency.
• Both BPC-157 and TB-500 are prohibited in competitive sports by WADA.

How This Works

BPC-157 is a synthetic pentadecapeptide (15 amino acids) originally isolated from human gastric juice. Preclinical research indicates it exerts cytoprotective effects across multiple organ systems, promotes angiogenesis, modulates nitric oxide pathways, and interacts with growth-factor systems involved in tissue repair. TB-500 (Thymosin b4) is a naturally occurring peptide that regulates actin polymerization, promotes cell migration, reduces inflammation, and supports wound healing and tissue regeneration. The combination is hypothesized to provide complementary mechanisms for accelerated musculoskeletal and soft-tissue recovery.

Benefits & Side Effects

Observations from preclinical and early clinical literature.

• Tissue Repair: Both peptides demonstrate wound-healing, tendon-repair, and anti-inflammatory

properties in animal models.

• Gastrointestinal Support: BPC-157 shows gastroprotective and ulcer-healing effects in preclinical

studies.

• Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose up to ~20

mg/kg); TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg.

• Possible Side Effects: Occasional mild injection-site reactions (redness, itching); rare reports of

transient dizziness or nausea; long-term human safety data remain limited.

Lifestyle Factors

Complementary strategies for best outcomes.

• Prioritize adequate protein intake to support tissue synthesis and repair.
• Combine with appropriate rehabilitation protocols when addressing musculoskeletal injuries.
• Ensure quality sleep and stress management to optimize recovery and healing responses.
• Stay hydrated and maintain balanced micronutrient intake (vitamins C, D, zinc) to support

connective-tissue health.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and injection site with alcohol; allow to dry completely.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue (use 23 to 25 gauge, 5/8 inch needle).
3. Aspiration is unnecessary for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, lateral thigh, upper arm, buttocks) to avoid lipohypertrophy.
5. For localized injuries, inject subcutaneously near (not into) the affected area when anatomically appropriate.

References

Source citations for further reading.

1. Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and neurotransmitter interactions (Biomedicines, 2022).
2. BPC 157 and standard angiogenic growth factors: GI tract healing and angiogenesis (Current Pharmaceutical Design, 2018).
3. Thymosin b4: roles in development, repair, and regeneration (Annals NY Academy of Sciences, 2007).
4. Thymosin b4: a multi-functional regenerative peptide (Expert Opinion on Biological Therapy, 2018).